Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Emtansine in HER2+ Advanced NSCLC
NCT02289833Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of trastuzumab emtansine in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Dec 2014; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02289833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289833.